CD8A and hepatocellular carcinoma: Furthermore, Farwell et al. developed an anti-CD8 radiolabeled minibody, named [89Zr]Df-IAB22M2C, to determine tumor CD8+ leukocyte distribution in patients with metastatic solid cancers (melanoma, NSCLC and hepatocellular carcinoma were included) [61].